Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
_ largest » _ large (Expand Search)
may mean » may lead (Expand Search), a mean (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
_ largest » _ large (Expand Search)
may mean » may lead (Expand Search), a mean (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Data Sheet 2_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated...
Published 2025“…Analysis of GP prescribing data in three volunteers allowed comparison of five-year periods immediately before and after starting continuous treatment. Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”
-
8
Data Sheet 1_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated...
Published 2025“…Analysis of GP prescribing data in three volunteers allowed comparison of five-year periods immediately before and after starting continuous treatment. Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”
-
9
-
10
-
11
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
12
-
13
-
14
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
17
-
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
19
-
20